Antiviral Drugs - Germany

Germany

In Germany, the revenue in the Antiviral Drugs market is expected to reach US$1.63bn by 2024.
This projection indicates that the market is poised for steady growth.
Furthermore, it is estimated that the revenue will experience an annual growth rate (CAGR 2024-2029) of 1.66%.
As a result, the market volume is anticipated to reach US$1.77bn by 2029.
In comparison to other countries, United States is expected to generate the highest revenue in the Antiviral Drugs market.
It is projected that United States will generate a staggering US$30,640.00m in revenue by 2024.
This highlights the prominence of the United States in the global market for Antiviral Drugs market.
Germany is at the forefront of developing and producing cutting-edge antiviral drugs, leveraging its strong pharmaceutical industry and research capabilities.

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

Antiviral drugs have been in high demand in Germany due to the rising incidence of viral infections. The country has a high prevalence of infectious diseases, with influenza and hepatitis being the most common. The Antiviral Drugs market in Germany has been growing steadily due to the increasing awareness about the benefits of antiviral drugs in treating viral infections.

Customer preferences: Customers in Germany prefer antiviral drugs that are effective and have fewer side effects. They are willing to pay a premium for drugs that are proven to be effective in treating viral infections. The demand for antiviral drugs is high among the elderly population who are more susceptible to viral infections.

Trends in the market: The Antiviral Drugs market in Germany has been witnessing the trend of increased research and development activities. Pharmaceutical companies are investing heavily in R&D to develop new and more effective antiviral drugs. The market is also witnessing the trend of increased partnerships and collaborations between pharmaceutical companies to develop new drugs.

Local special circumstances: Germany has a well-developed healthcare system, which has contributed to the growth of the Antiviral Drugs market. The country has a high rate of vaccination coverage, which has helped in reducing the incidence of viral infections. However, the country has been witnessing an increase in the number of cases of viral infections, which has led to an increase in the demand for antiviral drugs.

Underlying macroeconomic factors: The Antiviral Drugs market in Germany is influenced by various macroeconomic factors, including the aging population, increasing healthcare expenditure, and rising incidence of viral infections. The country has a large aging population, which is more susceptible to viral infections. The government has been increasing healthcare expenditure to improve the healthcare system, which has contributed to the growth of the Antiviral Drugs market. The rising incidence of viral infections has also led to an increase in the demand for antiviral drugs.In conclusion, the Antiviral Drugs market in Germany has been growing steadily due to the increasing awareness about the benefits of antiviral drugs in treating viral infections. Customers in Germany prefer antiviral drugs that are effective and have fewer side effects. The market is witnessing the trend of increased research and development activities and partnerships between pharmaceutical companies. The country's well-developed healthcare system, high rate of vaccination coverage, and increasing healthcare expenditure have contributed to the growth of the Antiviral Drugs market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.